|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Double-Blind, Placebo-Controlled Alcohol Study of Hythiam, Inc.'s Prometa Treatment Program Demonstrated Statistically Significant Improvement in Patients with Symptoms of Alcohol Withdrawal
7/8/2008 9:15:08 AM
LOS ANGELES--(BUSINESS WIRE)--Hythiam, Inc. (NASDAQ:HYTM) announced that the initial results of a double-blind, placebo-controlled study utilizing Hythiam’s PROMETA® Treatment Program (PROMETA) were presented at the Research Society on Alcoholism (RSA) conference in Washington, DC, by leading alcoholism expert and RSA President, Raymond Anton, M.D., of Medical University of South Carolina. At the time of the RSA presentation, the data presented covered the initial 6-week active treatment phase of the 14-week study. The study was designed to evaluate the impact of PROMETA on percent days abstinent, other use measures and cravings. Alcoholic subjects were stratified into 2 groups upon enrollment: those with higher alcohol withdrawal, as defined by their Clinical Institute Withdrawal Assessment (CIWA) scores, and those with lower CIWA scores. Subjects were not required to maintain prior abstinence. The key study findings are:
|
|
|
|
|
|
|
|
|
|
|